2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112668
    Retagliptin phosphate 1256756-88-3 99.71%
    Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research.
    Retagliptin phosphate
  • HY-123011
    Henagliflozin 1623804-44-3 98.05%
    Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research.
    Henagliflozin
  • HY-123785
    ORM-10962 763926-98-3 99.49%
    ORM-10962 is a potent, highly selective sodium-calcium exchanger (NCX) inhibitor, with IC50 values of 67 and 55 nM for the reverse and forward mode inhibition, respectively. ORM-10962 shows antiarrhythmic effect.
    ORM-10962
  • HY-135516
    Dalosirvat 1360540-81-3 98.22%
    Dalosirvat (SM-04554) is a potent Wnt activator with an EC50s of 28-29 nM. Dalosirvat can be used in the study of cancer.
    Dalosirvat
  • HY-147301
    Resomelagon 1809420-71-0 98.79%
    Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC1 and MC3. Resomelagon induces ERK1/2 phosphorylation and Ca2+ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research.
    Resomelagon
  • HY-14860A
    1-Deoxynojirimycin hydrochloride 73285-50-4
    1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.
    1-Deoxynojirimycin hydrochloride
  • HY-112885A
    nor-NOHA acetate 1140844-63-8 ≥99.0%
    nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA acetate
  • HY-15206S1
    Glyburide-d3 1219803-02-7 99.64%
    Glyburide-d3 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
    Glyburide-d3
  • HY-15398S3
    Vitamin D3-d3 80666-48-4 98.45%
    Vitamin D3-d3 is the deuterium labeled Vitamin D3. Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.
    Vitamin D3-d3
  • HY-102079
    SAFit1 1643125-32-9 ≥98.0%
    SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a Ki of 4±0.3 nM.
    SAFit1
  • HY-132924
    BMS-963272 1441057-15-3 99.02%
    BMS-963272 is an orally active and selective MGAT2 inhibitor (IC50 = 7.1 nM), used for the study of metabolic disorders and inflammatory diseases.
    BMS-963272
  • HY-134377
    Bocidelpar 2095128-20-2 98.08%
    Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD).
    Bocidelpar
  • HY-145061
    ADAMTS-5-IN-3 2688733-96-0 98.89%
    ADAMTS-5-IN-3 (Example 37-2) is a potent inhibitor of ADAMTS-5 and ADAMTS-4 with IC50s of 8 and 12 nM, respectively. ADAMTS-5-IN-3 can be used for the research of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis.
    ADAMTS-5-IN-3
  • HY-14892A
    Gemigliptin tartrate 1374639-74-3 99.52%
    Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.
    Gemigliptin tartrate
  • HY-P99725
    Marstacimab 1985638-39-8
    Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
    Marstacimab
  • HY-117727A
    Leriglitazone hydrochloride 146062-46-6 99.64%
    Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone hydrochloride, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone hydrochloride can be used in the study of neuroinflammatory and neurodegenerative diseases.
    Leriglitazone hydrochloride
  • HY-10473
    Eprotirome 355129-15-6 ≥99.0%
    Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research.
    Eprotirome
  • HY-13529
    Globalagliatin 1234703-40-2 99.45%
    Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with an EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes.
    Globalagliatin
  • HY-14925
    Lapaquistat 189059-71-0 99.81%
    Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy.
    Lapaquistat
  • HY-15133
    PTP1B-IN-3 809272-64-8 99.69%
    PTP1B-IN-3 is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 has antidiabetic and anticancer effects.
    PTP1B-IN-3
Cat. No. Product Name / Synonyms Application Reactivity